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AbstrACt
Introduction The success rate of weight loss 
maintenance is limited. Therefore, the purpose of this 
study is to investigate the maintenance of weight loss 
and immunometabolic health outcomes after diet- 
induced weight loss followed by 1- year treatment with 
a glucagon- like peptide-1 receptor agonist (liraglutide), 
physical exercise or the combination of both treatments as 
compared with placebo in individuals with obesity.
Methods and analysis This is an investigator- initiated, 
randomised, placebo- controlled, parallel group trial. 
We will enrol expectedly 200 women and men (age 
18–65 years) with obesity (body mass index 32–43 kg/
m2) to adhere to a very low- calorie diet (800 kcal/day) 
for 8 weeks in order to lose at least 5% of body weight. 
Subsequently, participants will be randomised in a 1:1:1:1 
ratio to one of four study groups for 52 weeks: (1) placebo, 
(2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/
day and (4) exercise 150 min/week+liraglutide 3.0 mg/
day. The primary endpoint is change in body weight from 
randomisation to end- of- treatment.
Ethics and dissemination The trial has been approved 
by the ethical committee of the Capital Region of Denmark 
and the Danish Medicines Agency. The trial will be 
conducted in agreement with the Declaration of Helsinki 
and monitored to follow the guidelines for good clinical 
practice. Results will be submitted for publication in 
international peer- reviewed scientific journals.
trial registration number 2015-005585-32
IntroduCtIon
Obesity is associated with increased risk of 
developing cardiovascular disease and type 
2 diabetes (T2D), along with increased risk 
of all- cause mortality.1 2 Obesity manage-
ment guidelines recommend weight loss 
of more than 5% of initial body weight to 
improve cardiometabolic risk factors, with 
greater weight loss producing greater bene-
fits.3 4 A 5%–10% weight loss improves lipid 
profile (~20% reduction in triglycerides, 
~15% reduction in low- density lipoprotein 
cholesterol, ~8% increase in high- density 
cholesterol levels),1 4 5 reduces systolic and 
diastolic blood pressure (~5 and ~4 mm Hg, 
respectively),3 6 reduces glycated haemo-
globin (HbA1c)3 4 and improves insulin sensi-
tivity.7–9 However, weight regain reverse these 
health benefits.10 11 Furthermore, intentional 
weight loss is typically followed by a 30%–50% 
regain of lost weight within the first year.12–14 
The main biological reasons for the rapid 
weight regain seem to be that weight loss 
causes a decrease in total energy expenditure 
to a degree that is greater than predicted 
from the decrease in fat and lean mass15 16 in 
combination with increased appetite in the 
weight- reduced state.17 18
Increasing energy expenditure by 
increasing physical activity is the first- line life-
style modification in the treatment of obesity 
along with reducing food intake. For exer-
cise interventions targeting general public 
health recommendations (at least 150 min/
week of moderate- intensity aerobic exercise), 
the associated weight loss is often modest 
strengths and limitations of this study
 ► First randomised controlled trial investigating the 
combined and individual effects of liraglutide and 
exercise to maintain diet- induced weight loss in in-
dividuals with obesity.
 ► Direct comparison of liraglutide and exercise on 
weight loss maintenance and immunometabolic 
health.
 ► Applying state- of- the- art methodologies, the 
study may identify novel targets for sustainable 
immunometabolic health- promoting weight loss 
strategies.
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Figure 1 Study design.
(0%–3%) without concomitant calorie restriction.19–21 
However, independent of weight loss, increasing physical 
activity improves body composition, glycaemic control, 
low- grade inflammatory profile and cardiorespiratory 
fitness in individuals with overweight and obesity.22–25 In 
addition, exercise may preserve lean mass during weight 
loss26 and thereby counteract the associated decrease in 
resting metabolic rate27 which may explain the observa-
tion that individuals performing regular exercise have 
less body weight regain after weight loss compared with 
participants that do not exercise.28 29
Glucagon- like peptide-1 (GLP-1) is an incretin 
hormone secreted from enteroendocrine L- cells in the 
gut after food intake. GLP-1 dose- dependently stimulates 
glucose- dependent insulin secretion thereby lowering 
blood glucose and reduces appetite and thereby food 
intake.30 31 32 33 Treatment for 56 weeks with the GLP-1 
receptor agonist (GLP-1 RA), liraglutide (3.0 mg), as an 
adjunct to regular diet and physical activity recommen-
dations has been shown to improve glycaemic control 
and induce moderate weight loss of 4.0% in patients with 
T2D34 and 5.4% in non- diabetic individuals with over-
weight or obesity35 compared with placebo. In addition, 
liraglutide has been shown to maintain a diet- induced 
weight loss over 56 weeks36 and maintain very low- calorie 
diet (VLCD)- induced improvements of fasting plasma 
glucose and triglycerides and prevent bone loss over 52 
weeks of weight loss maintenance superior to similar diet- 
induced weight loss maintenance in obese non- diabetic 
individuals.18 37
Obesity is associated with chronic low- grade inflamma-
tion38–40 which is linked to the development of atheroscle-
rosis and insulin resistance.41–43 Physically active individuals 
have lower inflammatory biomarker concentrations than 
their inactive counterparts,24 possibly explained by anti- 
inflammatory effects of an acute bout of exercise44 and 
lower levels of visceral adipose tissue.45 GLP-1 has also 
emerged as an immunomodulatory agent.46 47 In mice, 
GLP-1 RA administration reduces macrophage accumu-
lation and inflammatory markers in the arterial wall,48 
adipose tissue49 and heart.50 Similarly, GLP-1 RAs have 
shown anti- inflammatory effects in human coronary artery 
endothelial cells and aortic endothelial cells.51 In humans 
with T2D, short- term GLP-1 RA treatment exerts anti- 
inflammatory actions, reflected by reduced levels of the 
macrophage activation molecule sCD16352 and reduced 
production of several proinflammatory markers, such as 
tumor necrosis factor-α, interleukin (IL)-1β and IL-6 in 
peripheral blood mononuclear cells.52 53 Another study 
showed no improvement of obesity- associated adipose 
tissue dysfunction in T2D patients after GLP- 1RA treat-
ment.54 One year treatment with GLP-1 RAs reduces the 
inflammation marker, high- sensitivity C- reactive protein, 
in overweight and obese individuals35 and T2D patients.55 
Notably, in patients with T2D and high cardiovascular 
disease risk, GLP-1 RAs reduced the rate of occurrence of 
first major cardiovascular event and mortality.56 57
Thus, both physical activity and GLP-1 RA treatment 
seem to facilitate weight loss maintenance, improve meta-
bolic health and reduce systemic inflammation. However, 
diet- induced weight loss decreases energy expenditure 
and increases appetite. We hypothesise that the combina-
tion of physical activity and liraglutide treatment improves 
weight loss maintenance and immunometabolic health 
since the decreased energy expenditure is targeted with 
exercise and the increased appetite with liraglutide.
objectives
The objectives of this study are to investigate the main-
tenance of weight loss and immunometabolic health 
outcomes over 52 weeks with liraglutide treatment, phys-
ical exercise and the combination in individuals with 
obesity after a VLCD.
MEthods And AnAlysIs
Participants, interventions and endpoints
Trial design
This study protocol describes an investigator- initiated, 
randomised, placebo- controlled, parallel group trial, the 
S- LiTE trial (acronym for ‘Synergy effect of the appetite 
hormone GLP-1 (LiragluTide) and Exercise on mainte-
nance of weight loss and health after a low calorie diet’). 
The trial is double- blinded with regards to study medi-
cation but not exercise intervention. The study design is 
outlined in figure 1.
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box 1 Eligibility criteria for participants in the s- litE trial
Inclusion criteria
 ► BMI: 32–43 kg/m2.
 ► Age: 18–65 years.
 ► Safe contraceptive method or menopause for women.
Exclusion criteria
 ► Patients diagnosed with any known serious chronic illness, includ-
ing type 1 or 2 diabetes (or a randomly measured fasting plasma 
glucose >7 mmol/L).
 ► Angina pectoris, coronary heart disease or congestive heart failure 
(NYHA Class III- IV).
 ► Severe renal impairment (creatinine clearance (GFR) <30 mL/min).
 ► Severe hepatic impairment.
 ► Inflammatory bowel disease.
 ► Gastroparesis.
 ► Cancer.
 ► Chronic obstructive lung disease.
 ► Psychiatric disease, a history of major depressive or other severe 
psychiatric disorders.
 ► The use of medications that cause clinically significant weight gain 
or loss.
 ► Previous bariatric surgery.
 ► A history of idiopathic acute pancreatitis.
 ► A family or personal history of multiple endocrine neoplasia type 2 
or familial medullary thyroid carcinoma.
 ► Osteoarthritis, which is judged to be too severe to manage the ex-
ercise programme.
 ► Pregnancy, expecting pregnancy or breast feeding.
 ► Allergy to any of the ingredients of the study medication: liraglutide, 
disodium phosphate dihydrate, propylene glycol, phenol, hydrochlo-
ric acid and sodium hydroxide.
 ► Regular exercise training at high intensity (eg, spinning)>2 hours per 
week.
BMI, body mass index; GFR, glomerular filtration rate; GLP, glucagon- like 
peptide-1; NYHA, New York Heart Association; S- LiTE, Synergy effect of the 
appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight 
loss and health after a low calorie diet.
Study setting
All examinations in the trial will be carried out at Depart-
ment of Endocrinology, Hvidovre University Hospital, 
and Department of Biomedical Sciences, University of 
Copenhagen, Denmark.
Study status
Recruitment of participants was initiated in September 
2016. Last participant last visit is planned for November 
2020.
Participants and recruitment
We will enrol expectedly 200 participants. Eligible partic-
ipants are adults (age 18–65 years) with obesity (body 
mass index (BMI) 32–43 kg/m2) and no known serious 
chronic illness (including type 1 and 2 diabetes). Inclu-
sion and exclusion criteria are listed in box 1. Recruit-
ment will be done via local newspapers, online media 
and flyers from Department of Endocrinology, Hvidovre 
University Hospital, and Department of Biomedical 
Sciences, University of Copenhagen. Individuals who 
agree to participate will be invited to a pre- screening that 
includes screening of the study eligibility criteria before 
being finally included in the study. Withdrawn subjects 
will not be replaced. Re- screening is allowed within the 
recruitment period.
Participant involvement
The design of the study was partly inspired by qualitative 
interviews of a similar participant group performed by an 
anthropologist.58 On completion of data analyses, results 
will be disseminated to all participants as a lay summary 
of the main findings.
Interventions
Diet-induced weight loss
Initially, all participants will undergo 8 weeks with a VLCD 
(Cambridge Weight Plan, 800 kcal/day) with the objec-
tive to lose at least 5% of body weight. Although some 
benefits may be evident already at modest weight loss of 
2%–3% (eg, triglycerides and HbA1c),3 a ≥5% cut- off 
is chosen because it is associated with improved cardio-
vascular disease risk factors59 and T2D prevention60 and 
thus generally considered a clinically meaningful weight 
loss.3 20 61 Participants will be instructed to eat four meal 
replacements per day containing approximately 200 kcal 
and to only drink water and non- caloric beverages. Partic-
ipants who have lost at least 5% of body weight after the 
8- week weight loss phase will be randomised to one of the 
four study groups: 52 weeks of treatment with (1) placebo, 
(2) exercise+placebo, (3) liraglutide or (4) exercise+lira-
glutide. After randomisation, participants will undergo a 
4- week phase- out plan with three daily Cambridge meal 
products and one regular meal the first week and two 
daily Cambridge meal products and two regular meals the 
three subsequent weeks.
Liraglutide or placebo
The GLP-1 RA, liraglutide (3.0 mg) (Saxenda, Novo 
Nordisk A/S, Bagsværd, Denmark) or placebo will be 
administrated once daily as subcutaneous injections in 
the abdomen or thigh. The starting dose is 0.6 mg with 
weekly increments of 0.6 mg until 3.0 mg is achieved. The 
titration procedure will be prolonged for participants 
who do not tolerate fast up- titration. Participants who do 
not tolerate the 3.0 mg dose may in special circumstances 
stay at lower dose (2.4 mg). However, the aim is to reach 
3.0 mg for all study participants.
Physical exercise
The exercise intervention follows the global recommen-
dations from the WHO of 150 min of moderate- intensity 
aerobic physical activity throughout the week or 75 min 
of vigorous- intensity aerobic physical activity throughout 
the week or an equivalent combination of moderate- and 
vigorous- intensity activity.62 The intervention consists of four 
sessions per week for a total of 150 min/week. Two sessions 
per week will be performed under supervision of the study 
staff and two sessions will be performed individually. A 
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heart rate monitor (Polar A300, Polar Electro Oy, Kempele, 
Finland) will be worn during all planned exercise sessions. 
Supervised sessions will consist of structured exercise for 
a duration of 45 min. Of this, 30 min will be interval- based 
spinning and 15 min will be circuit training focusing on 
large muscle groups. Individual exercise sessions will 
include aerobic exercise such as cycling, rowing or elliptical 
training as well as brisk walking and/or cycling to work. 
Participants will be advised to primarily perform non- weight 
bearing activities. The target aerobic exercise intensity is 
80% of maximal heart rate. Participants randomised to an 
exercise group will undergo a 6- week ramp- up phase with 
one session in weeks 1 and 2, two sessions in weeks 3 and 4, 
and three sessions in weeks 5 and 6 before exercising four 
times per week from weeks 7 to 52. If the planned ramp- up 
phase with exercise is not possible (eg, due to side effects 
of study medication or joint pain), ramp- up will proceed 
more slowly. Participants not randomised to exercise will be 
instructed to maintain habitual physical activity according 
to level before entering the trial.
Liraglutide and physical exercise
Combination of the two interventions described above.
The trial will end at week 52 after randomisation where 
liraglutide 3.0 mg/placebo and exercise treatment will be 
discontinued. One year after the intervention, the partici-
pants will be invited for a follow- up visit.
Criteria for discontinuing/modifying allocated interventions
Participants may withdraw from the intervention at any 
time. Withdrawn participants will be invited for the 
planned examinations at week 52 unless written consent is 
withdrawn. Participants may be withdrawn from the trial at 
the discretion of the investigator due to a safety concern 
or a serious violation of the protocol. Participants will be 
withdrawn in occurrence of pregnancy or at the intention 
to become pregnant.
Endpoints
Primary endpoint
The primary endpoint is change in body weight from after 
the initial weight loss phase (baseline/V1) to end of treat-
ment after 52 weeks (end/V3).
Secondary endpoint
The secondary endpoints are changes in body composition 
(lean/fat mass ratio) and metabolic health (glucose toler-
ance, lipid status, waist circumference, blood pressure) 
from V1 to V3.
Explorative endpoints
Explorative endpoints include changes from V1 to V3 in 
the following parameters: meal- related appetite hormone 
response; physical fitness and determination of daily 
physical activity and sleep; systemic markers of immu-
nometabolism; endothelial function; immunometa-
bolic changes in the subcutaneous adipose tissue; gene 
expression profile of circulating inflammatory cells; bone 
health; food preferences and subjective appetite sensation; 
faecal bacterial composition; plasma metabolomics and 
proteomics; epigenetics of spermatozoa.
Sample size calculation
Sample size is calculated in relation to body weight. 
In our previous weight loss maintenance study,18 the 
response within each treatment group was normally 
distributed with SD of 5.5 kg. Thus, with expectedly 30 
participants completing each study arm we will be able 
to detect a true difference of 4 kg between groups with a 
power of 0.8, assuming a two- sided α-level of 0.05. In our 
previous study, 10% did not complete the initial weight 
loss phase.18 Thus, with expectedly 200 enrolled study 
participants and an expected dropout rate of 25% after 
randomisation, we expect to have at least 30 participants 
from each study arm to complete the trial.
Assignment of intervention
Treatment allocation
After the initial 8- week VLCD phase, participants will be 
randomised after the test day to one of the four study groups 
in a 1:1:1:1 ratio in accordance with a subject randomisation 
list (SRL) provided by Novo Nordisk (NN). A non- blinded 
study nurse (not otherwise associated with the trial) will 
allocate study participants according to the SRL. Rando-
misation will be stratified by sex (male/female) and age 
(below/above 40 years). NN will provide a total dispensing 
unit number list (TDL). The non- blinded study nurse will 
allocate trial medication using the TDL by matching a six- 
digit dispensing unit number (DUN) to the correct treat-
ment. Each box of study medication will be labelled with 
a unique DUN. The DUN alone is not unblinding. Thus, 
dispensing of trial medication to subjects can be carried out 
by blinded trial staff by selecting the DUN provided by the 
non- blinded study nurse.
Unblinding
The SRL and the TDL are stored on site at Hvidovre 
Hospital with restricted access only to the designated non- 
blinded study nurse. Study ID of the participant is matched 
with the SRL and TDL which reveals if trial medication is 
liraglutide or placebo. Preferably, the non- blinded study 
nurse will perform any unblinding of study participants. 
However, if needed, all trial staff (sponsor, investigator 
and sub- investigators) can get access to the SRL and TDL 
and perform the unblinding procedure. Unblinding can 
be performed under the following circumstances: treat-
ment of a participant in a medical emergency that requires 
knowledge of treatment allocation; treatment of a partici-
pant for an adverse event (AE); in the event of a suspected 
unexpected serious adverse reaction (SUSAR); in the 
event that the participant's study medication is acciden-
tally taken by a member of their household, for example, 
a child; for the submission of trial data to the Data Moni-
toring and Safety Committee for the monitoring of safety 
and/or efficacy.
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Table 1 Overview of study visits
Visit Prescreening V0 V1 V2 V3 V4
Time point (week) – -8 0 26 52 104
Informed consent X           
Anamnesis X           
Inclusion/exclusion criteria X           
Demographics X           
Pregnancy test   X X   X   
Adverse events   X X X X   
Body weight X X X X X X
Waist and hip circumference   X X X X X
Blood pressure and heart rate   X X X X X
Fasting blood samples   X X X X X
7- day accelerometry   X X X X X
Adipose tissue biopsy   X X X X   
DXA scan   X X   X X
Liquid meal test   X X   X   
Faecal, urine, saliva and semen   X X   X   
FMD   X X   X   
ECG   X X   X   
Physical fitness testing   X X   X   
Questionnaires   X X   X X
Food preference test   X X   X X
DXA, dual- energy X- ray absorptiometry; FMD, flow- mediated dilation.
data collection, management and analysis
Study visits
Identical test days will take place before the initial weight 
loss phase (screening/V0), after initial weight loss (base-
line/V1) and after 52 weeks of treatment (end/V3) 
(figure 1). Furthermore, a visit will be performed after 26 
weeks of treatment (mid/V2). An overview of performed 
assessments is provided in table 1. During the weight loss 
phase, weekly consultations will be conducted to assess 
compliance to the VLCD, including measurement of 
body weight and handing out Cambridge meal prod-
ucts. During the 52- week weight maintenance phase, 
weight consultations, including assessment of AEs, will be 
conducted at weeks 1, 2, 3, 4, 9, 13, 17, 22, 32, 39 and 46. 
Consultations at weeks 4, 13 and 39 will include collection 
of fasting blood samples, measurement of hip and waist 
circumference, blood pressure and resting heart rate. 
Finally, participants will be invited to complete a post- trial 
unsupervised follow- up visit (V4) 1 year after intervention 
completion.
Criteria for assessments
 ► Participants must be fasting for minimum 10 hours 
prior to test days, including foods, liquids and medi-
cation (except study medication).
 ► Study medication should preferably be taken on the 
morning of the tests.
 ► Exercise should not be performed the day before or 
in the morning before tests.
Assessments
Anthropometrics
Body weight will be measured on a digital scale (TANITA 
WB- 110MA, Tokyo, Japan) to the nearest 0.1 kg without 
shoes and wearing light clothes. Waist circumference, the 
midpoint between lowest rib and iliac crest, and hip circum-
ference, the level of the great trochanters, will be measured 
in duplicate to the nearest 0.1 cm after gentle expiration.
DXA scan
Dual- energy X- ray absorptiometry (DXA) scans will be 
performed in fasting state to measure body fat mass, 
fat free mass and bone density (Hologic Discovery A, 
Hologic, Bedford, USA).
Blood pressure
Blood pressure and resting heart rate will be measured 
in duplicate from the non- dominant arm with a digital 
blood pressure monitor (Microlife BP A3 plus, Widnau, 
Switzerland) in sitting position after at least 5 min of rest.
Fasting blood samples
Fasting blood samples will be collected to measure circu-
lating biomarkers of metabolic health, appetite hormones, 
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immune markers, plasma proteomics and plasma metab-
olomics. Furthermore, peripheral blood mononuclear 
cells will be isolated and DNA will be collected. A set of 
standard samples will be collected and analysed on the 
same day for participants’ safety, including: haemoglobin, 
free calcium, creatinine and estimated glomerular filtra-
tion rate, potassium, sodium, C- reactive protein, alanine 
aminotransferase, amylase, alkaline phosphatase, vitamin 
D, glycated haemoglobin, parathyroid hormone, thyro-
tropin and blood lipids.
Adipose tissue biopsy
Subcutaneous abdominal adipose tissue biopsies (~1 g) 
will be obtained by needle aspiration under local anaes-
thesia using 5–10 mL 0.5% lidocaine. From adipose 
tissue biopsies, gene expression will be determined from 
reverse transcription- qPCR: proinflammatory and anti- 
inflammatory adipocytokines, adipocyte differentiation 
markers and markers of macrophage infiltration. The 
immune cells of the adipose tissue will be isolated to eval-
uate macrophage sup- populations and activation status 
(single cell analysis).
Meal test
After fasting blood sampling, a liquid meal (Nutricia 
Nutridrink, 600 kcal, 49.0 E% from carbohydrates, 35.2 
E% from fat and 15.8 E% from protein) will be ingested 
over 15 min, and blood samples will be collected contin-
uously every 15 min for the first hour and every 30 min 
for the next 2 hours to measure circulating biomarkers of 
metabolic health, appetite hormones, immune markers, 
plasma proteomics and plasma metabolomics. During the 
meal test, appetite sensation will be assessed after each 
blood sample using a visual analogue scale.63
Faeces, urine, saliva and semen
Faeces samples will be collected to investigate faecal bacte-
rial composition. Semen will be collected (if relevant) to 
investigate epigenetics of the spermatozoa. Additionally, 
urine and saliva samples will be collected.
Endothelial function
Flow- mediated dilation (FMD) of the brachial artery will 
be measured to assess endothelial function.64 FMD, also 
known as endothelium- dependent vasodilation, is the vaso-
dilatory response of the brachial artery to increased shear 
stress and reflects the ability of vascular endothelium to 
produce nitric oxide. The brachial artery will be scanned 
with high resolution ultrasound imaging using a linear 
probe at rest and during hyperaemia. Hyperaemia will be 
induced by inflation and deflation of a sphygmomanom-
eter cuff around the forearm, distal to the site scanned with 
ultrasound. FMD is calculated as the percentage change of 
the brachial artery diameter from rest to 60 s after the cuff 
is released. To assess the endothelium- independent vaso-
dilation, nitroglycerine is given sublingually (0.4 mg) with 
the diameter of the brachial artery measured before and 
5 min after drug administration. Carotid intima- media 
thickness will also be measured using ultrasound.
Electrocardiography
ECG will be performed to assess safety concerns related to 
study participation.
Physical fitness
Measurement of physical fitness will include three 
components: (1) cardiorespiratory fitness (peak oxygen 
consumption) will be assessed with an incremental 
maximal cycle protocol performed on an electromag-
netically braked cycle ergometer (Corival, Lode Medical 
Technology, The Netherlands) with continuously deter-
mined oxygen consumption and carbon dioxide produc-
tion (MasterScreen CPX, CareFusion, Germany). After 
a warm- up protocol, workload will be increased every 
minute (20 and 25 watt for females and males, respec-
tively) until attainment of peak oxygen consumption 
based on the following criteria: plateau in oxygen 
consumption, respiratory exchange ratio above 1.15 or 
attainment of age- predicted maximal heart rate (220 
minus age) and voluntary exhaustion.65 (2) Physical func-
tioning will be measured as time to ascend and descend 
an 11- step stairway twice. (3) Maximal strength will be 
measured as isometric maximal voluntary contraction 
force of the dominant thigh using a dynamometer chair 
(Good Strength, Metitur Oy, Jyväskylä, Finland).66 67
Questionnaires
Participants will answer five questionnaires to determine 
self- rated quality of life (The Short Form (36) Health 
Survey68), eating habits (three- factor eating question-
naire69), physical activity (International Physical Activity 
Questionnaire70), sleep quality (Pittsburgh Sleep Quality 
Index71) and self- efficacy (General Self- Efficacy Scale72).
Food preferences
Food preferences and food reward responses will be 
measured in fasted state and postprandially with the Leeds 
Food Preference Questionnaire.73 This is a computerised 
task where standardised pictures of 20 typical Danish food 
items are shown in the categories: high fat savoury, low fat 
savoury, high fat sweet and low fat sweet. Participants are 
instructed to rate each individual food item according to 
liking and to systematically choose the food items they 
prefer the most. Speed of choices is covertly assessed as 
an index of implicit wanting.
Free-living assessment of physical activity and sleep
An accelerometer device (GENEActiv, ActivInsights Ltd, 
UK) will be worn on the wrist for seven consecutive days 
and nights with concomitant sleep registration (time for 
going to and out of bed) to assess habitual physical activity 
and sleep duration.
Data management
Participants will be identified by study ID. Study data are 
collected and managed using the REDCap secure web- 
based system74 hosted by the Capital Region of Denmark, 
where electronic case report forms (CRF) have been 
created. During the trial, data will be entered directly 
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into REDCap by study personnel. Extraction procedures 
will be performed by investigators or sponsor. Laboratory 
data will be transferred electronically from the laboratory 
performing clinical analyses and will be archived in secured 
hard drives with backup. All biological material (blood, 
adipose tissue, faeces, urine, saliva and semen) obtained 
from study participants will be kept in a research bio- bank. 
Samples will be labelled with study ID. The bio- bank allows 
for analyses of samples to be performed simultaneously 
to avoid large instrumental variations. The research bio- 
bank will be terminated no later than 1 August 2036. After 
this date, the remains of the material will be transferred 
to a regular bio- bank in Denmark. In order to access this 
material, a new protocol must be approved by an ethics 
committee. The Danish Data Protection Agency has been 
notified about the trial and the trial adheres to the Data 
Protection Act which requires data to be anonymised as 
soon as it is practical to do so.
Data analysis plan
Analyses will be based on two defined analysis sets: an 
intention- to- treat (ITT) analysis set and a per- protocol 
(PP) analysis set. ITT includes all randomised participants 
exposed to at least one dose of trial product or exercise that 
have completed the visit at week 4. PP will include all partic-
ipants who complete the 52 week intervention with ≥75% 
compliance to the interventions. Safety analysis will be 
performed on the ITT analysis set. Two- tailed tests will be 
performed and the significance level will be set to α=0.05.
Primary endpoint
The change from V1 to V3 in body weight (kg) will be anal-
ysed using a general linear model with treatment group as 
explanatory variable and baseline weight or BMI, age, sex 
and initial weight loss (if relevant) as covariates. We will use 
drug treatment (liraglutide, placebo), exercise (yes, no) 
and their interaction to investigate the effects of drug and 
exercise. Adequacy of model assumptions will be assessed 
using graphical models, and outcome variables may be 
logarithmically transformed if considered necessary to 
meet the assumptions of linearity, variance homogeneity 
and/or normality of residuals. The objective of the analysis 
is to determine whether the effect on body weight of lira-
glutide 3.0 mg in combination with exercise programme 
is different from (1) placebo and (2) to either treatments 
alone, and to quantify the extend of this difference. Weight 
change over time will also be assessed by repeated measures 
analyses as appropriate (linear mixed model with an appro-
priate covariance structure and a suitably described effect 
over time). Blinding of study medication allocation will be 
kept for investigators until analysis of the primary endpoint 
has been completed.
Secondary and exploratory endpoints
For secondary and exploratory endpoints, general linear 
models will be used to test for differences. The change 
from V1 to V3 will be analysed using general linear 
models with treatment group as explanatory variable and 
baseline weight or BMI, age, sex and initial weight loss 
(if relevant) as covariates. Longitudinal data will also be 
analysed using linear mixed models as described above.
Auditing
The Good Clinical Practice (GCP) unit of the Univer-
sity Hospitals of Copenhagen will perform on- site audits 
minimum once yearly to ensure that the trial adhere to 
the guidelines for good clinical practice provided by the 
International Council for Harmonisation (ICH).
dIsCussIon
Obesity prevalence has increased dramatically in the 
past decades,75 and the high recidivism rates after inten-
tional weight loss13 29 emphasise a strong need for new 
effective strategies to promote sustainable weight loss 
maintenance in individuals with obesity. The present 
protocol describes the first randomised controlled trial to 
investigate GLP-1 RA treatment combined with physical 
exercise in the context of long- term weight loss mainte-
nance. The results have the potential to reveal a novel 
approach of combined lifestyle and pharmacological 
intervention that may provide substantial improvements 
of body weight, body composition and immunometabolic 
health in obesity. Additionally, by applying state- of- the- art 
methodologies, the study may identify novel targets for 
future immunometabolic health- promoting weight loss 
interventions.
EthICs And dIssEMInAtIon
harms
All AEs will be collected from the first drug adminis-
tration and in all following contacts with participants 
throughout the trial. A serious AE (SAE) is defined as any 
untoward medical occurrence that results in death, is life- 
threatening, requires hospitalisation or prolongation of 
existing hospitalisation, results in persistent or significant 
disability/incapacity, or is a congenial anomaly or birth 
defect. Once yearly, sponsor will send a report regarding 
SARs occurring in the trial and safety of the study partic-
ipants with regard to continuation of the trial to the 
Danish Medicines Agency and the Ethics Committee. In 
case of any deadly or life- threatening SUSAR, sponsor will 
immediately (and no later than 7 days after becoming 
aware) notify the Danish Medicines Agency and the 
Ethics Committee. No later than 8 days after reporting 
of a SUSAR, sponsor will notify the Danish Medicines 
Agency and the Ethics Committee of all relevant informa-
tion about sponsor’s and investigator’s follow- up of the 
SUSAR. All other SUSARs will be reported to the Danish 
Medicines Agency and the Ethics Committee no later 
than 15 days after sponsor becoming aware of this. All 
AEs and SAEs will be noted in the CRF and recorded in 
the End- of- Trial Form to the Danish Medicines Agency 
and in the report to the Ethics Committee (if requested) 
no later than 90 days after trial completion.
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Ethical considerations
Liraglutide 3.0 mg will be given with injection pen. Lira-
glutide 3.0 mg is an approved drug and the dosage will 
be kept within the approved maximum (3.0 mg). Liraglu-
tide 3.0 mg is safe but may cause transient nausea during 
the first weeks. Other side effects include dizziness, 
insomnia (transient) and gall stones. Uncommon/rare 
side effects include dehydration, inflamed gall bladder, 
allergic reactions and reduced kidney function. Placebo 
injections should not cause any discomfort. There should 
not be any discomfort to the injection if performed as 
prescribed. The Cambridge Weight Plan is used in daily 
clinical practice and is considered safe but may cause 
constipation, fatigue, headache and dizziness. The exer-
cise programme does not exceed the recommendations 
from WHO.76 However, participants are not habitual 
exercisers. Therefore, careful considerations regarding 
the ramp- up of the exercise intervention will be given. 
Furthermore, most of the exercise is non- weight bearing 
activity in an attempt to limit potential injuries associated 
with the exercise intervention. The discomfort associated 
with the planned assessments is considered minimal. 
Applying a peripheral venous catheter for blood samples 
collection can cause transient discomfort, irritation and 
redness around the puncture site. Some discomfort might 
be experienced when applying local anaesthesia for the 
adipose tissue biopsy. The biopsy itself should only cause 
minimal discomfort. DXA scans use radiation with a radi-
ation dose of approximately 0.02 mSv per examination. 
This dose is very low compared with the background radi-
ation in Denmark (approximately 3 mSv/year). The FMD 
and carotid intima- media thickness ultrasound scans do 
not use radiation. Applying nitroglycerine may cause 
transient headache, dizziness, decreased blood pressure 
and increased heart rate. Half- life of nitroglycerine is 
1–3 min. Nitroglycerine will not be used if systolic blood 
pressure is under 100 mm Hg. The risks that are associ-
ated with this study are assessed as minimal. By partici-
pating in this project, the participants will contribute with 
new important knowledge about the interaction between 
GLP-1 and exercise and their importance for weight loss 
maintenance and metabolic health. Overall, we consider 
that any potential risks and side effects are outweighed by 
the advantages of participation. The trial will be carried 
out in accordance with the Declaration of Helsinki and 
adhere to the GCP- ICH guidelines. After careful written 
and oral information about the trial and associated risks 
have been given, a written informed consent form will be 
obtained by investigator or sub- investigators before any 
study- related activities are performed. An English transla-
tion of the informed consent form is provided in online 
supplementary file 1.
dissemination plan
All study results (positive, negative and inconclusive) will 
be presented at international scientific conferences as 
oral presentations or poster presentations. Furthermore, 
results will be published in international peer- reviewed 
scientific journals.
Protocol version
The study protocol was approved on 30 June 2016. 
The present manuscript details the latest version of the 
protocol (version 9) approved on 6 October 2018.
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